Earlier this year, GSK executives explained to Fierce Biotech why they felt the company’s push into oligonucleotides was such a good fit. | Earlier this year, GSK executives explained to Fierce Biotech why they felt the company’s push into oligonucleotides was such a good fit. Now, the British Big Pharma has added further depth to this strategy courtesy of a research collaboration with Elsie Biotechnologies.
